Interpretation software for NGS diagnostics, 12/14

December 2014—Omicia, a genome interpretation company, announced the commercial availability of Opal Clinical, the company’s software-as-a-service solution for diagnostic testing organizations. With Opal Clinical, users can launch NGS tests faster and interpret results more accurately and quickly, the company said in a statement.

Features include support for targeted gene panels and whole-exome or genome tests; complete clinical interpretation workflow to speed turnaround time; the generation of lab-branded physician-ready clinical reports and application programming interfaces for integration with LIMS and EHRs; comprehensive variant curation within panels to accelerate patient interpretation; and HIPAA and CLIA compliance.

Omicia, 510-595-0800